Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in symptomatic intracranial atherosclerotic stenosis
NCT05741086Phase 3Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of evolocumab in intracranial atherosclerosis (ICAD) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Plaque burden at 1 year, Degree of stenosis caused by the plaque at 1 year and 5 more. Status: unknown.
02
Drugs
evolocumab
03
Conditions
intracranial atherosclerosis (ICAD)
Beyond the preview
Go deeper on NCT05741086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741086.